

Treatment of Varieties of Dermatitis and *Malassezia* Yeasts

Malassezia, treatment, alkaline salts,
earth alkaline salts, pityriasis, atopic
dermatitis, head-neck dermatitis

DESCRIPTION OF TECHNOLOGY / PRODUCT

We offer compounds consisting of alkaline salts and earth alkaline salts usable for treatment and prophylaxis of dermatitis and other *malassezia*-associated diseases.



SCOPE OF APPLICATION

Malassezia-associated diseases among humans and animals like seborrheic eczema, pityriasis, atopic dermatitis, head-neck-dermatitis, dandruff, psoriasis, onychomycosis among humans and *malassezia*-dermatitis and otitis among dogs and cats are quite common. Some *malassezia*-strains are already resistant to the known anti-mycotic drugs. Several of the known anti-mycotic drugs are poisonous to the environment. Therefore, we can see a great need for non-toxic compounds to treat *malassezia*-associated diseases.

AT A GLANCE ...

TECHNOLOGY FIELD / SCOPE OF APPLICATION

Compounds for treating *malassezia*-associated diseases

MARKET / BRANCH

- Pharmaceutical companies
- Chemical companies
- Cosmetics companies
- Pharmaceutical products
- Cosmetic care products

USP

- Non-toxic, selective to *malassezia* yeasts, non-allergic compound for topical application among humans and animals
- New compounds are very unlikely to cause resistant *malassezia*-strains because of the unique mode of action of the new compounds

DEVELOPMENT STATUS

- ✓ Positive evaluation of fungicide effects in yeast cultures
- Next steps: Clinical evaluation of the compounds

PATENT PORTFOLIO

Priority application filed on January 2016 in the European Patent Office, pending;
Further applications in PCT member states possible.

REFERENCE NO.: **TM 884**

ADVANTAGES COMPARED TO STATE OF THE ART

The new compounds are non-toxic and non-allergenic. The new compounds are very unlikely to cause resistant *malassezia*-strains because of their unique mode of action. The new compounds are easily producible and processible to a pharmaceutical composition.

DEVELOPMENT STATUS

In vitro tests of the new compounds showed a convincing effect against several *malassezia*-strains.

MARKET POTENTIAL

Malassezia-associated diseases like atopic dermatitis or pityriasis and cosmetic problems like dandruff are quite common and cause not only physical but also psychological harm in affected patients, especially because of the prominent skin alterations. Therefore, most patients are very compliant to undergo a therapeutic or prophylactic treatment.

OFFER

On behalf of its shareholder Justus-Liebig-Universität Giessen, TransMIT GmbH is looking for cooperation partners or licensees in Germany, Europe, US, and Asia.

A TECHNOLOGY OF



REFERENCE NO.: **TM 884**

CONTACT:

TransMIT Gesellschaft für
Technologietransfer mbH
Kerkrader Strasse 3
35394 Giessen
Germany
www.transmit.de
www.hipo-online.net

Contact person:

Niklas Günther, M.A.
Phone: +49 (0)641 94 36 4 – 53
Fax: +49 (0)641 94 36 – 55
E-Mail: niklas.guenther@transmit.de



System Partner for Innovation